Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
A phase 3 trial of Sacituzumab tirumotecan, Doxorubicin, Paclitaxel / nab-paclitaxel in endometrial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) is a phase 3 interventional study registered as NCT06132958 by Merck Sharp & Dohme LLC, with 710 participants planned, started 2023-12-06 and due to reach its primary completion in 2028-01-10. Interventions recorded: Sacituzumab tirumotecan, Doxorubicin, Paclitaxel, Nab-paclitaxel, Rescue medications. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan
Shares Sacituzumab tirumotecan, Paclitaxel / nab-paclitaxel, Endometrial cancer, Merck & Co. (MSD).
- TrialA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Shares Sacituzumab tirumotecan, Doxorubicin, Merck & Co. (MSD).
- TrialStudy of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Im
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, Endometrial cancer.
- TrialPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287
Shares Sacituzumab tirumotecan, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD).
- TrialPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, Endometrial cancer.
- TrialA Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Shares Sacituzumab tirumotecan, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD).
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD).
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc
Shares Sacituzumab tirumotecan, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD).